IRX Therapeutics Raises $8 Million to Develop Therapeutic Vaccines for Cancer and Viral Diseases

IRX Therapeutics, Inc. a private biopharmaceutical company headquartered in New York and dedicated to the discovery and development of proprietary therapies for the treatment of cancer and viral diseases, recently completed an $8 million financing through a note and warrant offering to its existing stockholders. IRX announced that the new funding will be used to further develop its pipeline of cancer vaccine candidates, including its lead product, IRX-2. Morrison Cohen represented IRX Therapeutics in the transaction. Please click on the PDF link above to read the full press release.